IL3RA is commonly expressed in acute myeloid leukemia (AML) and classic Hodgkin lymphoma (HL) (25), In order to provide an opportunity for the use of IL3RA directed antibody drug conjugates (ADC) in the treatment of AML and HL, on December 21, 2018, The US Food and Drug Administration (FDA) has approved Tagraxofusp Erzs for the treatment of plasmacytoid dendritic cell tumors in adults and children of 2 years and older (26). Here, IL3RA is linked to Hodgkins lymphoma.